Search by Drug Name or NDC
NDC 47781-0335-30 Pyridostigmine Bromide 180 mg/1 Details
Pyridostigmine Bromide 180 mg/1
Pyridostigmine Bromide is a ORAL TABLET, EXTENDED RELEASE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Alvogen, Inc.. The primary component is PYRIDOSTIGMINE BROMIDE.
MedlinePlus Drug Summary
Pyridostigmine is used to decrease muscle weakness resulting from myasthenia gravis.
Related Packages: 47781-0335-30Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Pyridostigmine
Product Information
| NDC | 47781-0335 |
|---|---|
| Product ID | 47781-335_210210e1-a038-858e-25e7-ba24b5206234 |
| Associated GPIs | 76000050100405 |
| GCN Sequence Number | 004765 |
| GCN Sequence Number Description | pyridostigmine bromide TABLET ER 180 MG ORAL |
| HIC3 | J1B |
| HIC3 Description | CHOLINESTERASE INHIBITORS |
| GCN | 18540 |
| HICL Sequence Number | 001990 |
| HICL Sequence Number Description | PYRIDOSTIGMINE BROMIDE |
| Brand/Generic | Generic |
| Proprietary Name | Pyridostigmine Bromide |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Pyridostigmine Bromide |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Active Ingredient Strength | 180 |
| Active Ingredient Units | mg/1 |
| Substance Name | PYRIDOSTIGMINE BROMIDE |
| Labeler Name | Alvogen, Inc. |
| Pharmaceutical Class | Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA204737 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 47781-0335-30 (47781033530)
| NDC Package Code | 47781-335-30 |
|---|---|
| Billing NDC | 47781033530 |
| Package | 30 TABLET, EXTENDED RELEASE in 1 BOTTLE (47781-335-30) |
| Marketing Start Date | 2015-06-29 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 3.7885 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | PYRIDOSTIGMINE ER 180 MG TAB |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |
This pricing file, entitled the NADAC (National Average Drug Acquisition
Cost) files, provide
state Medicaid agencies with covered outpatient drug prices by averaging
survey invoice
prices from retail community pharmacies across the United States. These
pharmacies include
independent retail community pharmacies and chain pharmacies. The prices
are updated on a
weekly and monthly basis